纯度 | >85%SDS-PAGE. |
种属 | Human |
靶点 | TCEAL7 |
Uniprot No | Q9BRU2 |
内毒素 | < 0.01EU/μg |
表达宿主 | E.coli |
表达区间 | 1-100aa |
氨基酸序列 | MQKPCKENEG KPKCSVPKRE EKRPYGEFER QQTEGNFRQR LLQSLEEFKE DIDYRHFKDE EMTREGDEME RCLEEIRGLR KKFRALHSNH RHSRDRPYPI |
预测分子量 | kDa |
蛋白标签 | His tag N-Terminus |
缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于TCEAL7重组蛋白的模拟参考文献示例(实际文献需通过学术数据库查询):
1. **"TCEAL7 modulates MYC transcription in ovarian cancer through chromatin remodeling"**
*作者:Smith J, et al. (2019)*
**摘要**:研究揭示了TCEAL7重组蛋白在卵巢癌细胞中通过抑制MYC转录活性调控肿瘤进展的机制,表明其作为抑癌因子的潜在作用。
2. **"Expression and purification of recombinant TCEAL7 in E. coli for functional characterization"**
*作者:Jones R, et al. (2020)*
**摘要**:报道了一种高效表达和纯化TCEAL7重组蛋白的方法,并验证了其与DNA结合的能力,为后续结构研究奠定基础。
3. **"TCEAL7 regulates cell cycle progression via p53-dependent pathways in breast cancer"**
*作者:Lee S, et al. (2021)*
**摘要**:通过体外实验证明TCEAL7重组蛋白通过激活p53通路诱导细胞周期停滞,抑制乳腺癌细胞增殖。
4. **"Comprehensive analysis of TCEAL protein family in transcriptional regulation"**
*作者:Brown K, et al. (2018)*
**摘要**:综述类文章,总结了TCEAL7等家族成员在转录调控中的功能多样性,强调其重组蛋白在疾病模型中的应用潜力。
**注意**:以上为模拟文献,建议通过PubMed、Google Scholar等平台检索真实文献(关键词:TCEAL7 recombinant protein, function, expression)。
**Background of TCEAL7 Recombinant Protein**
TCEAL7 (Transcription Elongation Factor A-like 7) is a member of the TCEAL family, a group of nuclear proteins implicated in transcriptional regulation and chromatin remodeling. Encoded by the *TCEAL7* gene located on the X chromosome, this protein contains a conserved TEA/ATTS DNA-binding domain, suggesting its potential role in modulating gene expression. While the precise molecular function of TCEAL7 remains under investigation, studies associate it with cellular processes such as differentiation, apoptosis, and tumorigenesis.
Recombinant TCEAL7 protein is engineered using heterologous expression systems (e.g., *E. coli* or mammalian cells) to produce purified, functional protein for research. Its recombinant form enables mechanistic studies, including protein-protein/DNA interactions, post-translational modifications, and pathway analysis. TCEAL7 has garnered attention in cancer biology due to its context-dependent roles. For instance, it acts as a putative tumor suppressor in ovarian cancer, where its downregulation correlates with poor prognosis, while in breast cancer, overexpression may drive oncogenic signaling via pathways like Wnt/β-catenin or p53.
Notably, TCEAL7’s involvement in stress responses and epigenetic regulation highlights its broader biological relevance. However, conflicting reports on its pro- or anti-tumor effects underscore the need for further research to clarify its molecular targets and regulatory networks. Recombinant TCEAL7 serves as a critical tool in dissecting these complexities, offering insights into its therapeutic potential in cancers and other diseases linked to transcriptional dysregulation.
×